Billerica, MA, November 17, 2021: ProterixBio, Inc. (CLIA: 22D2189261) today announced it has received a Clinical Laboratory Permit from New York State Department of Health. This permit enables ProterixBio to now perform certain laboratory procedures on specimens accepted from New York State. Together with other accreditations obtained by ProterixBio the company is now licensed to provide such laboratory services across all 50 States.

“Receiving this Permit enables us to extend the reach of our immunoassay expertise and accelerate our efforts to address unmet clinical needs with high-quality protein biomarker analysis.” – Andrew Abrams, Chief Executive Officer of ProterixBio.

For more information, contact Chief Executive Officer, Andrew Abrams, at aabrams@proterixbio.com.